Sgarra, Luca <br/><br/>
Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology.  [electronic resource] 

 -  American journal of physiology. Endocrinology and metabolism  May 2012 
 - E1171-82 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1522-1555 
<br/><br/><label>Standard No.: </label>10.1152/ajpendo.00038.2012  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Coronary Artery Disease--drug therapy<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Disease Progression<br/>Endothelium, Vascular--drug effects<br/>Humans<br/>Hypoglycemic Agents--adverse effects<br/>Risk Assessment<br/>Risk Factors<br/>Rosiglitazone<br/>Thiazolidinediones--administration & dosage